# Feasibility of Semaglutide in Advanced Lung Disease

> **NCT05746039** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 8 (estimated)

## Conditions studied

- Obesity
- Interstitial Lung Disease
- Chronic Obstructive Pulmonary Disease
- Sarcoidosis, Pulmonary
- Pulmonary Hypertension

## Interventions

- **DRUG:** Semaglutide Pen Injector

## Key facts

- **NCT ID:** NCT05746039
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-29
- **Primary completion:** 2027-12-28
- **Final completion:** 2027-12-28
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05746039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05746039, "Feasibility of Semaglutide in Advanced Lung Disease". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05746039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*